Anticoagulant effects of nafamostat administered via central venous catheter versus the ECMO circuit in adults receiving ECMO support.
Аннотация
OBJECTIVES
To investigate the impact of administering nafamostat through central venous catheter versus extracorporeal membrane oxygenation (ECMO) circuit on anticoagulation efficacy during ECMO support.
MATERIALS AND
METHODS
This retrospective study included patients who received nafamostat for anticoagulation during ECMO support. Collected clinical data included age, sex, body weight, indication for ECMO, medical history, vital signs, laboratory test results, complications, and clinical outcomes. Patients were categorized into a central venous administration group and an ECMO-circuit administration group according to the site of nafamostat administration. Clinical parameters and outcomes were compared between the two groups.
RESULTS
A total of 102 patients were included in the analysis. The mean age was 51 ± 9 years, with 61 (59.8%) males and 41 (40.2%) females. There were no statistically significant differences between the two groups in age, body weight, sex distribution, ECMO indications, medical history, vital signs, laboratory findings, or acute physiology and chronic health evaluation II (APACHE II) scores (P > 0.05). The incidence of membrane oxygenator thrombosis was significantly higher in the central venous group than in the ECMO-circuit group (32.6% vs. 12.5%, P < 0.05). Central venous infusion of nafamostat was associated with an increased risk of membrane oxygenator thrombosis (OR:3.491, 95%CI 1.270-9.593, P < 0.05). The time required to achieve the anticoagulation target was significantly longer in the central venous group [4 (3-5) vs. 3 (3-4) hours, P < 0.05], and the mean daily dose of nafamostat was also significantly higher (1210 ± 261 vs. 1084 ± 132 mg, P < 0.05).
CONCLUSIONS
Compared with central venous infusion, administration of nafamostat via the ECMO circuit was associated with a lower incidence of membrane oxygenator thrombosis, more rapid achievement of the anticoagulation target, and a lower daily dosage requirement. These findings are hypothesis-generating and require confirmation in prospective studies before informing clinical decisions regarding the route of nafamostat administration.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.